CC-99282 Clinical Trials

Size	Price	Qty
5mg	USD 719
25mg	USD 1,970

Clinical Trials

Multiple clinical trials are currently evaluating CC-99282 (golcadomide) across Phase I and Phase II studies for various B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, high-grade B-cell lymphoma, and relapsed or refractory non-Hodgkin lymphoma. Sponsored by pharmaceutical companies and academic entities, these protocols encompass active recruiting, active non-recruiting, and completed statuses. Together, these trials evaluate the safety, pharmacokinetics, and therapeutic efficacy of CC-99282 as a targeted therapy.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05283720	ACTIVE_NOT_RECRUITING	Non-Hodgkin Lymphoma	Genmab	2022-06-14	PHASE2
NCT06835530	RECRUITING	Diffuse Large B Cell Non-Hodgkin Lymphoma	Fondazione Italiana Linfomi - ETS	2025-04-09	PHASE2
NCT05169515	ACTIVE_NOT_RECRUITING	Non-Hodgkin Lymphoma	Hoffmann-La Roche	2022-10-26	PHASE1
NCT04884035	ACTIVE_NOT_RECRUITING	Lymphoma, B-Cell	Celgene	2021-09-15	PHASE1
NCT06108232	RECRUITING	Follicular Lymphoma; Tumor	M.D. Anderson Cancer Center	2024-03-15	PHASE2
NCT03930953	ACTIVE_NOT_RECRUITING	Lymphoma, Non-Hodgkin	Celgene	2019-05-20	PHASE1; PHASE2
NCT06209619	RECRUITING	B-Cell Non-Hodgkin Lymphoma-Recurrent; Diffuse Large B-Cell Lymphoma-Recurrent; Follicular Lymphoma-Recurrent; High Grade B-Cell Lymphoma-Recurrent; Primary Mediastinal Large B-Cell Lymphoma-Recurrent; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent; B-Cell Non-Hodgkin Lymphoma-Refractory; Diffuse Large B-Cell Lymphoma-Refractory; Follicular Lymphoma-Refractory; High Grade B-Cell Lymphoma-Refractory; Primary Mediastinal Large B-Cell Lymphoma-Refractory; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory	Nathan Denlinger	2024-01-29	PHASE1
NCT04434196	COMPLETED	Lymphoma, Non-Hodgkin	Celgene	2020-12-21	PHASE1
NCT03310619	COMPLETED	Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular	Celgene	2017-12-20	PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-07)

Check the CC-99282 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

CC-99282 functions as an oral cereblon (CRBN) E3 ligase modulator that binds CRBN, co-opting its ubiquitin ligase complex to induce the selective proteasomal degradation of transcription factors Ikaros and Aiolos. This targeted depletion downregulates essential survival signaling pathways in malignant B-lymphocytes to trigger apoptosis, providing the biological mechanism for suppressing tumor growth in clinical conditions such as diffuse large B-cell lymphoma and follicular lymphoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).